Literature DB >> 6306626

Cyclic adenine nucleotide levels in lymphocytes from patients with systemic sclerosis: efficiency of prostaglandin infusions.

I B Kovacs, P M Dowd, J D Kirby, P Turner.   

Abstract

Basal intracellular cAMP levels of lymphocytes from patients with systemic sclerosis, all suffering from Raynaud's phenomenon, were significantly lower than those obtained from normal controls. Moreover, the cAMP response to isoprenaline of these patients' lymphocytes was inhibited. Intravenous infusion of prostaglandins (E1 and I2) restored the basal levels and greatly improved the responsiveness of the cells to isoprenaline stimulation.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6306626      PMCID： PMC2417475          DOI： 10.1136/pgmj.59.690.241

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  5 in total

1.  Rise and fall of cyclic AMP required for onset of lymphocyte DNA synthesis.

Authors:  T Wang; J R Sheppard; J E Foker
Journal:  Science       Date:  1978-07-14       Impact factor: 47.728

2.  Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis.

Authors:  R M Bernstein; J C Steigerwald; E M Tan
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

3.  Prostacyclin increases cyclic-nucleotide responsiveness of lymphocytes from patients with systemic sclerosis.

Authors:  J D Kirby; D R Lima; P M Dowd; S Kilfeather; P Turner
Journal:  Lancet       Date:  1980-08-30       Impact factor: 79.321

4.  Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).

Authors:  P M Dowd; M F Martin; E D Cooke; S A Bowcock; R Jones; P A Dieppe; J D Kirby
Journal:  Br J Dermatol       Date:  1982-01       Impact factor: 9.302

5.  Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS, scleroderma).

Authors:  T Inoshita; T L Whiteside; G P Rodnan; F H Taylor
Journal:  J Lab Clin Med       Date:  1981-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.